Related Experiment Video
Updated: Oct 29, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Bringing Advanced Therapies for Parkinson's Disease to the Clinic: The Scientist's Perspective
Mark Tomishima1, Agnete Kirkeby2,3
1BlueRock Therapeutics, New York, NY, USA.
Abstract:
After many years of preclinical development, cell and gene therapies have advanced from research tools in the lab to clinical-grade products for patients, and today they constitute more than a quarter of all new Phase I clinical trials for Parkinson's disease. Whereas efficacy has been convincingly proven for many of these products in preclinical models, the field is now entering a new phase where the functionality and safety of these products will need to stand the test in clinical trials. If successful, these new products can have the potential to provide patients with a one-time administered treatment which may alleviate them from daily symptomatic dopaminergic medication.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Clinical Trials: Overview
Preclinical Development: Overview
EPS and iPS Cells in Disease Research
Drug Discovery: Overview

